MAPT and Alzheimer disease: However, some studies demonstrated the facilitation of the clearance of soluble Aβ peptides by ApoE, the reversal of cognitive deficits (Cramer et al., 2012; Fitz et al., 2013; Muñoz-Cabrera et al., 2020), and the prevention of the effect of ApoE4 on tau hyperphosphorylation (Boehm-Cagan and Michaelson, 2014) after bexarotene administration to mouse models of AD.